Your Clotting Risk Is Hidden in Your DNA. Here's What Your Genes Say.

Factor V is a protein your liver makes that’s essential for blood clotting. When you cut yourself, Factor V springs into action, binding to other clotting factors to form a stable blood clot. But your body also has built-in brakes. A protein called activated protein C naturally inactivates Factor V once the clot has done its job, preventing clots from growing too large or traveling where they shouldn’t. This is a perfectly balanced system in people without variants.

Factor V Leiden is a single amino acid change (R506Q) in the region of Factor V where activated protein C normally attaches. Here’s the problem: the Leiden variant makes Factor V resistant to this natural shutdown signal. Instead of being inactivated in minutes, it keeps working for hours or longer. Roughly 5% of people with European ancestry carry this variant, making it one of the most common inherited clotting disorders. People with Factor V Leiden have a 4 to 8 times higher risk of deep vein thrombosis or pulmonary embolism. If you’re a woman on oral contraceptives, that risk multiplies another 10 fold.

You might never feel Factor V Leiden working. Most carriers never develop a clot. But the risk is constant. If you travel for 10 hours on a plane, your clotting risk spikes because blood pools in your legs and Factor V keeps the clot-forming machinery active. If you have surgery and stay immobilized for days, the same amplified risk applies. If you become pregnant or start hormonal contraception, your clotting cascade speeds up system-wide, and Leiden makes it faster still.

Prothrombin is the inactive precursor to thrombin, the central enzyme that converts fibrinogen into fibrin, the protein that actually forms the mesh of a blood clot. Your liver produces prothrombin constantly. When you bleed, a cascade of signals converts prothrombin into active thrombin, which immediately begins constructing the clot. Once the bleeding stops, inhibitors shut down thrombin and the clot stabilizes. This is evolution’s elegant solution to the clotting problem: make it fast when needed, stop it when done.

The F2 G20210A variant sits in the regulatory region upstream of the prothrombin gene, where transcription factors bind to control how much prothrombin gets made. People with the A allele produce more prothrombin than normal, creating a higher baseline of clot-forming machinery in their blood. Roughly 2 to 3% of Europeans carry this variant. The extra prothrombin raises your clotting risk 2 to 3 times above baseline. Critically, F2 variants interact with Factor V Leiden; if you carry both, your risk compounds.

You won’t feel your prothrombin level rising. But your blood is more primed to clot. After surgery, your recovery includes a period of immobilization where clotting risk is already elevated by the surgical trauma itself. With elevated prothrombin, that risk intensifies. During pregnancy, when the clotting cascade naturally accelerates to prepare for blood loss during delivery, extra prothrombin pushes you into genuinely high-risk territory. Understanding your F2 status is especially critical if you also carry F5 Leiden.

MTHFR catalyzes one of the most critical steps in your methylation cycle: converting 5,10-methylenetetrahydrofolate into 5-methyltetrahydrofolate, the form of folate your body uses to methylate homocysteine into methionine. This reaction is essential because elevated homocysteine damages blood vessel walls, activates clotting factors, and directly increases thrombosis risk independent of cholesterol or blood pressure. Your cardiovascular system depends on MTHFR doing this job efficiently every single day.

The MTHFR C677T variant reduces the enzyme’s activity by 40 to 70%. Roughly 40% of people of European ancestry carry at least one copy of the T allele. When MTHFR is impaired, homocysteine accumulates in your blood, directly increasing your arterial and venous thrombosis risk. The effect is especially pronounced if you’re also deficient in B12, B6, or folate, since these vitamins are cofactors in homocysteine metabolism. If you carry both MTHFR C677T and Factor V Leiden, your cardiovascular risk profile shifts upward on both the arterial and venous sides.

You might feel this as fatigue, brain fog, or mood changes, since methylation fuels energy and neurotransmitter synthesis. But the cardiovascular cost is silent. Your blood vessels are under constant low-level inflammatory stress from elevated homocysteine. Your clotting factors are slightly more activated. Over years, this compounds into atherosclerosis, clot formation, or stroke. Most doctors never check homocysteine levels, so they miss the connection entirely.

PAI1 encodes a protein that inhibits the very enzymes responsible for dissolving blood clots. Plasminogen activators are the body’s natural clot-busters; they convert plasminogen into plasmin, which chops up fibrin strands and dissolves old clots. PAI1 acts as the brake on this system. Without PAI1, clots would dissolve too fast and you’d bleed from minor injuries. With too much PAI1, clots persist longer than they should, increasing thrombosis risk. The balance between clot formation and clot dissolution is one of the most finely tuned systems in your body.

The PAI1 4G/5G polymorphism alters how much PAI1 gets produced. People with the 4G/4G genotype produce more PAI1 than those with 5G alleles. Roughly 25% of the population is 4G/4G homozygous. High PAI1 producers have slower clot breakdown, which increases both venous thromboembolism risk and cardiovascular event risk. The effect is amplified if you also carry Factor V Leiden or elevated prothrombin, since you’re then forming clots faster while also dissolving them slower, a double jeopardy scenario.

You won’t consciously experience your PAI1 status. But after an injury or surgery, your clots persist in your circulation longer than they should. If you’re immobilized on a long flight or recovering from an operation, the clots that form don’t dissolve at the normal rate, letting them grow or travel. PAI1 also rises with inflammation, obesity, and stress, so its effect isn’t static; it’s a variable risk factor that changes with your health status.

NOS3 produces nitric oxide (NO) in the endothelial cells lining your blood vessels. Nitric oxide is one of the most powerful vasodilators known. When your arteries need to expand to increase blood flow, endothelial cells release nitric oxide, which relaxes the smooth muscle in vessel walls and allows dilation. Nitric oxide also prevents platelets from sticking to vessel walls and clotting factors from accumulating. It’s essentially a vasculoprotective signal that keeps your blood vessels clean and responsive. Without sufficient nitric oxide, your vessels become stiff, clot-prone, and hypertensive.

The NOS3 Glu298Asp variant (rs1799983) reduces the efficiency of nitric oxide production. Roughly 30 to 40% of people carry this variant. People with the Asp allele produce less nitric oxide, leading to reduced vasodilation, elevated blood pressure, and increased atherosclerosis and thrombosis risk. The effect compounds if you carry Factor V Leiden, because not only is your blood more prone to clotting (due to F5), but your vessels are also less able to dilate and prevent clot formation (due to low NO). It’s a two-hit process.

You might experience this as exercise intolerance, unusual shortness of breath during exertion, or a tendency toward high blood pressure even with a normal lifestyle. Your blood vessels aren’t responding normally to the demand for blood flow. If you have an event like a prolonged plane flight or surgery, the reduced nitric oxide means your vessels have fewer defenses against clot formation and adhesion.

VKORC1 encodes vitamin K oxide reductase, an enzyme that recycles vitamin K into its active form (KH2). Vitamin K is essential for activating clotting factors II, VII, IX, and X, which are the protein backbone of the coagulation cascade. Your liver constantly uses and recycles vitamin K to keep these clotting factors functional. Without functional VKORC1, clotting factors would remain inactive and bleeding risk would soar. VKORC1 is also the target of warfarin, a blood thinner that blocks VKORC1 to reduce clotting factor activation.

The VKORC1 -1639G>A variant alters how much enzyme gets made. People with the A allele produce less VKORC1 and are therefore more sensitive to warfarin. Roughly 40 to 50% of Europeans carry the A allele in at least one copy. If you carry VKORC1 A alleles and ever need warfarin, you’ll require lower doses to achieve the same anticoagulation effect as G/G carriers. This isn’t an immediate thrombosis risk; it’s a pharmacogenetic fact that changes how anticoagulation is managed. Standard warfarin dosing will over-anticoagulate you, raising bleeding risk.

You won’t feel VKORC1 variants unless you’re on warfarin and having dosing problems. But if you carry Factor V Leiden and develop a clot requiring anticoagulation, knowing your VKORC1 status could prevent dangerous bleeding episodes. It’s the kind of information that only matters in a specific scenario, but in that scenario, it’s critical. Your genes encode how your body metabolizes blood thinners; that’s information worth having before you need it.